Novavax’s COVID-19 booster to be evaluated in NIH study

35850 novavaxs covid 19 booster to be evaluated in nih study

Novavax Inc. NVAX, +1.58% said Friday that its experimental COVID-19 booster is being tested in a Phase 1/2 clinical trial sponsored by the National Institutes of Health. This study is evaluating Novavax’s protein-based booster candidate in people who have already received the primary series of shots developed by BioNTech SE BNTX, +2.45% and Pfizer Inc. PFE, +0.77%, Johnson & Johnson JNJ, +0.52%, or Moderna Inc. MRNA, +0.53%. (Novavax’s COVID-19 vaccine has not been authorized in the U.S.; it is currently being reviewed by the Food and Drug Administration.) The study is enrolling 1,130 adults; approximately 180 of them will receive the Novavax shot as a booster. Novavax’s stock has declined 43.0% so far this year, while the S&P 500 SPX, +1.43% is down 5.1%.

Source: Marketwatch

Related Posts